Skip to content

Study of Pathyadi Churna in Amavata

UPSHAYATMAK STUDY OF PATHYADI CHURNA IN AMAVATA (R.A.) WITH SPECIAL REFRENCE TO Anti-cyclic citrullinated peptide (anti-CCP) antibody LEVEL. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/083563
Enrollment
60
Registered
2025-03-27
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M049- Autoinflammatory syndrome, unspecified

Interventions

None listed

Sponsors

RACHANA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient with presence of classical sign and symptoms along with modern parameter of Amavaat (RA). 2. Age group between 20-60 yrs. 3. Patients giving informed consent for the trial.

Exclusion criteria

Exclusion criteria: 1. Patient below the age of 20 yrs. and above 60 yrs. 2. Patients who left the treatment in between the study 3. Patients who are steroid dependent for relief of symptom 4. Patients representing with complication like SLE, Endocarditisetc 5. Patients with contractures of joints of severe deformities will not be included. 6. Patient having all classical sign and symptoms of Amavata.

Design outcomes

Primary

MeasureTime frame
Releif in the sign and symptoms of AmavataTimepoint: 1st day, 15th day, one month

Secondary

MeasureTime frame
It may be a boon to provide such a cost- effective & safe medicine to the society as many people suffer from this troublesome disease which can end up in a series of complications & disturbed life, stress & uneasiness. Once the stablishment of effectiveness of pathyadi churna inAmavata, the more effective prepration can be obtained.Timepoint: 1st day, 15th day, one month

Countries

India

Contacts

Public ContactRachana Tiwari

Shubhdeep Ayurved Medical College and Hospital

drrachnatiwari@gmail.com8225002466

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026